This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...